Activity is consistent with routine post-exercise selling to cover taxes or diversify holdings, not an unusual signal. Monitor next 10-Q for any change in revenue trajectory or guidance that could contextualize timing. No immediate read-through for trading strategy.
How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Apr 21 $573.46entry
- T+1 · 7mo ago +0.14%α −0.87% · $574.29
- T+5 · 7mo ago −0.76%α −1.84% · $569.11
- T+20 · 6mo ago −1.16%α −5.37% · $566.80
- T+60 · 4mo ago −6.59%α −12.16% · $535.67
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Three key insiders at United Therapeutics, including CEO Martine Rothblatt, CFO James Edgemon, and Director Christopher Patusky, collectively sold $2.46 million in open-market transactions over a 7-day period. The sales follow routine derivative exercises, with Patusky accounting for 67% of the total dollar volume. Total open-market proceeds represent just 0.01% of the company's $25.1B market cap.
Key Financial Metrics
Key Facts
- CEO Martine Rothblatt sold $948,381 in open-market transactions across three dates (2026-04-20 to 2026-04-22).
- Director Christopher Patusky sold $1,655,790 in shares on 2026-04-24, following full exercise of options.
- CFO James Edgemon sold $503,649 in shares on 2026-04-20 after exercising 10,000 options.
- All sales were preceded by option exercises; no insider made a net open-market sale without prior exercise.
- Total open-market sale value ($2.46M) represents only 0.01% of UTHR's $25.1B market cap.
Financial Impact
$2.46 million in open-market sales over 7 days (0.01% of market cap)
Risk Factors
- Perception risk if media mischaracterizes the cluster as broad insider pessimism.
- Potential for short-term sentiment pressure despite lack of economic significance.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-UTHR-1777062710654 |
Track record
123 reports on UTHR
4 of 9 bullish or bearish reports moved the stock their way by T+5. Best: +10.30% at T+20 after the Oct 14, 2026 report. 5 of 9 went positive at some point.
Filters
- Nov 16, 2026today Insider Cluster Neutral 3/10 Entry price pending
- Nov 13, 20263d ago Insider Cluster Bearish 4/10 Entry $597.50 Now $587.88 +1.61% settles Nov 23
- Nov 12, 20264d ago Insider Cluster Neutral 2/10 Entry $591.17 Now $587.88 −0.56% settles Nov 20
- Nov 10, 20266d ago Insider Cluster Neutral 2/10 Entry $595.66 Now $587.88 −1.31% settles Nov 18
- Nov 9, 20267d ago Insider Cluster Neutral 2/10 Entry $588.61 Now $587.88 −0.12% settles Nov 17
- Nov 9, 20267d ago 144 Neutral 2/10 Entry $588.61 Now $587.88 −0.12% settles Nov 17
- Nov 6, 202610d ago Insider Cluster Neutral 2/10 Entry $582.46 to $587.88 Now $587.88 +0.93% ▲ +0.93% +2.62% vs SPY
- Nov 5, 202611d ago Insider Cluster Neutral 2/10 Entry $562.02 to $591.17 Now $587.88 +4.60% ▲ +5.19% +2.59% vs SPY
- Nov 5, 202611d ago 144 Neutral 2/10 Entry $562.02 to $591.17 Now $587.88 +4.60% ▲ +5.19% +2.59% vs SPY
- Nov 4, 202612d ago SC 13G/A Neutral 2/10 Entry $565.72 to $593.31 Now $587.88 +3.92% ▲ +4.88% +1.59% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers